

NEWS RELEASE

May 8, 2017

Otsuka Pharmaceutical Factory enters into an agreement to acquire additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited (OPI)

Otsuka Pharmaceutical Factory, Inc. (OPF), which holds 60% equity in the Indian joint venture subsidiary, Otsuka Pharmaceutical India Private Limited* (OPI), has reached an agreement to acquire all the OPI shares held by Claris Lifesciences Limited (Claris) (20% of outstanding shares). To this extent, the two companies have signed a Stock Purchase Agreement. The shareholding ratio after the purchase of the shares will be OPF: 80% and Mitsui and Company (Mitsui): 20%. The share transfer is subject to the approval of FIPB (Foreign Investment Promotion Board of India).

On July 31, 2013, OPF, together with Claris and Mitsui, has established a joint venture company, and since then, OPI has been operating its iv solutions business based on the business transferred from Claris.

With this increase in the shareholdings of OPI, OPF will be able to maximize the utilization of the technology of basic iv solution and clinical nutrition that it has acquired throughout the years in Japan, and will strengthen its business in India, a country in which significant economic growth and increasingly sophisticated healthcare system are expected.

Going forward, under Otsuka Group's corporate philosophy, "Otsuka-people creating new products for better health worldwide," OPF with its partner Mitsui will contribute to the betterment of health of the people of India.

* OPI has changed its name from Claris Otsuka Private Limited to Otsuka Pharmaceutical India Private Limited on March 1, 2017.

Company Profile

Otsuka Pharmaceutical India Private Limited

| | | |
|--|---|--|
| Date of Establishment of the Joint Venture | : | July 31, 2013 |
| Capital | : | 10.524 billion INR (approximately 17.9 billion JPY) |
| Investment Ratio | : | (Before share transfer) OPF: 60%, Claris: 20%, Mitsui: 20% (After share transfer) OPF: 80%, Mitsui: 20% |
| Representative | : | Shuichi Takagi, CEO |
| Head office | : | Ahmedabad, Gujarat, India |
| Employees | : | 1,059 (as of December 31, 2016) |
| Scope of Business | : | Manufacture and distribution of basic solution and clinical nutrition products |
| Business Area | : | India and over 50 countries worldwide |
| Website (URL) | : | http://www.otsukapharma.in/ |

Otsuka Pharmaceutical Factory, Inc.

| | | |
|-------------------|---|---|
| Established | : | October 7, 1969 |
| Capital | : | 80 million yen |
| Representative | : | Shinichi Ogasawara, President and Representative Director |
| Head office | : | 115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima, Japan |
| Employees | : | 2,309 (as of December 31, 2016) |
| Scope of Business | : | Manufacture, sale, import and export of clinical nutrition products, and other pharmaceutical products, medical devices, and functional foods, etc. |
| Website (URL) | : | http://www.otsukakj.jp/en/ |